Last reviewed · How we verify
ACCS100
ACCS100 is an investigational drug that works by binding to and inhibiting the activity of a specific molecular target.
ACCS100 is an investigational drug that works by binding to and inhibiting the activity of a specific molecular target. Used for Investigated for the treatment of gastrointestinal disorders.
At a glance
| Generic name | ACCS100 |
|---|---|
| Also known as | HSCAS, UPSN, NS, Air Classified Calcium Silicate |
| Sponsor | Texas Enterosorbents Incorporated |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of ACCS100 is not well understood, but it is believed to involve the inhibition of a key enzyme involved in the regulation of the gut microbiome.
Approved indications
- Investigated for the treatment of gastrointestinal disorders
Common side effects
- Gastrointestinal side effects
Key clinical trials
- Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100" (PHASE2)
- Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACCS100 CI brief — competitive landscape report
- ACCS100 updates RSS · CI watch RSS
- Texas Enterosorbents Incorporated portfolio CI